Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes
Clinical trial NCT01035879 · COMPLETED
Trial details
- NCT number
- NCT01035879
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-12-01
- Primary completion
- 2010-08-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.